Sandra D.  van der Vaart net worth and biography

Sandra van der Vaart Biography and Net Worth

Sandy van der Vaart has served as Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Corporate Secretary since February 2020.

Prior to her current role, Sandy served as Senior Vice President, Global General Counsel, Chief Compliance Officer and Corporate Secretary. Prior to that, she served as Labcorp’s Senior Vice President, Deputy Chief Legal Officer from September 2015 until February 2019 and Senior Vice President, General Counsel and Assistant Secretary from January 2009 to September 2015. She has been with Labcorp since 2001 and has served in various other roles within the legal department. Prior to joining Labcorp, Sandy was a member of the Health Care Practice Group with Smith, Helms, Mulliss & Moore, and also previously worked for the North Carolina Medical Society as Director of the Society’s Managed Care Department. She is a member of the Association of Corporate Counsel and previously served as Chair of the Health Law Section Council of the North Carolina Bar Association and as President of the North Carolina Society of Healthcare Attorneys. Sandy obtained her B.S. in nursing from the University of North Carolina at Chapel Hill and her J.D. from the University of Virginia School of Law.

What is Sandra D. van der Vaart's net worth?

The estimated net worth of Sandra D. van der Vaart is at least $1.52 million as of March 28th, 2024. Ms. van der Vaart owns 7,637 shares of Laboratory Co. of America stock worth more than $1,523,123 as of April 19th. This net worth approximation does not reflect any other investments that Ms. van der Vaart may own. Learn More about Sandra D. van der Vaart's net worth.

How old is Sandra D. van der Vaart?

Ms. van der Vaart is currently 64 years old. There are 7 older executives and no younger executives at Laboratory Co. of America. Learn More on Sandra D. van der Vaart's age.

How do I contact Sandra D. van der Vaart?

The corporate mailing address for Ms. van der Vaart and other Laboratory Co. of America executives is 358 South Main Street, BURLINGTON NC, 27215. Laboratory Co. of America can also be reached via phone at (336) 229-1127 and via email at [email protected]. Learn More on Sandra D. van der Vaart's contact information.

Has Sandra D. van der Vaart been buying or selling shares of Laboratory Co. of America?

Sandra D. van der Vaart has not been actively trading shares of Laboratory Co. of America within the last three months. Most recently, Der Vaart Sandra D. Van sold 3,553 shares of the business's stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $216.74, for a transaction totalling $770,077.22. Following the completion of the sale, the executive vice president now directly owns 7,637 shares of the company's stock, valued at $1,655,243.38. Learn More on Sandra D. van der Vaart's trading history.

Who are Laboratory Co. of America's active insiders?

Laboratory Co. of America's insider roster includes Kerrii Anderson (Director), Jean-Luc Belingard (Director), Brian Caveney (EVP), Glenn Eisenberg (CFO), Dwight Gilliland (Director), Paul Kirchgraber (CEO), Peter Neupert (Director), Mark Schroeder (EVP), Amy Summy (CMO), Sandra van der Vaart (EVP), Peter Wilkinson (CAO), and R. Williams (Director). Learn More on Laboratory Co. of America's active insiders.

Are insiders buying or selling shares of Laboratory Co. of America?

During the last year, insiders at the medical research company sold shares 14 times. They sold a total of 66,701 shares worth more than $14,419,280.01. The most recent insider tranaction occured on April, 1st when COO Mark S Schroeder sold 6,477 shares worth more than $1,407,387.33. Insiders at Laboratory Co. of America own 0.9% of the company. Learn More about insider trades at Laboratory Co. of America.

Information on this page was last updated on 4/1/2024.

Sandra D. van der Vaart Insider Trading History at Laboratory Co. of America

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/28/2024Sell3,553$216.74$770,077.227,637View SEC Filing Icon  
2/13/2024Sell237$226.45$53,668.657,637View SEC Filing Icon  
2/8/2024Sell259$222.06$57,513.547,637View SEC Filing Icon  
6/29/2023Sell212$240.00$50,880.007,605View SEC Filing Icon  
2/7/2023Sell219$243.01$53,219.195,341View SEC Filing Icon  
2/3/2023Sell173$253.90$43,924.705,341View SEC Filing Icon  
9/15/2021Sell4,500$296.78$1,335,510.00View SEC Filing Icon  
6/7/2021Sell4,500$266.56$1,199,520.009,737View SEC Filing Icon  
7/2/2020Sell435$170.00$73,950.004,044View SEC Filing Icon  
6/24/2020Sell872$160.33$139,807.764,915View SEC Filing Icon  
2/13/2020Sell208$188.49$39,205.922,819View SEC Filing Icon  
2/10/2020Sell133$181.99$24,204.67View SEC Filing Icon  
7/8/2019Sell2,328$176.75$411,474.002,328View SEC Filing Icon  
See Full Table

Sandra D. van der Vaart Buying and Selling Activity at Laboratory Co. of America

This chart shows Der Vaart Sandra D Van's buying and selling at Laboratory Co. of America by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Laboratory Co. of America Company Overview

Laboratory Co. of America logo
Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; and drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.
Read More

Today's Range

Now: $200.74
Low: $199.65
High: $201.32

50 Day Range

MA: $214.16
Low: $199.44
High: $228.11

2 Week Range

Now: $200.74
Low: $174.20
High: $234.09

Volume

184,302 shs

Average Volume

729,324 shs

Market Capitalization

$16.89 billion

P/E Ratio

42.99

Dividend Yield

1.44%

Beta

1.01